Life-Threatening Bleeding
Get the facts.
Patients At Risk
  • ~408 patients each day are expected to be hospitalized with an apixaban- or rivaroxaban- related bleed in 20181
  • ~70 patients die each day following hospitalization from apixaban- or rivaroxaban- related bleeds1-3
Intracranial Hemorrhage (ICH)
  • Substantial hematoma expansion (volume increase of ≥33% or ≥6 mL) occurred in approximately 40% of ICH patients taking NOACs4
  • 44% of intracerebral hemorrhage patients on apixaban or rivaroxaban experience a substantial hematoma expansion within 6 hours of presentation5
  • In non-valvular atrial fibrillation clinical trials, 48% of rivaroxaban patients (Rocket AF Trial) and 45% of apixaban patients (Aristotle Trial) with ICH died within 30 days3,6
Gastrointestinal Bleed
  • Results from randomized controlled trials show that gastrointestinal bleeds account for 39%-56% of all major bleeds in rivaroxaban- or apixaban-treated patients7,8
Andexxa is for patients taking rivaroxaban or apixaban who are experiencing life- threatening or uncontrolled bleeding, due to
  • Intracranial Hemorrhage
    • Intracerebral, subdural, subarachnoid
  • Bleeding at a Critical Site
    • Intraocular, pericardial, intraspinal, intrarticular
  • Major Bleed with Hemodynamic Instability
    • Including, but not limited to: gastrointestinal, retroperitoneal, genitourinary tract
  • Major Trauma
    • Blunt or penetrating injury
Dosing and Reconstitution